Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 600 Shares

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 600 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $36.02, for a total transaction of $21,612.00. Following the sale, the chief financial officer directly owned 88,240 shares in the company, valued at $3,178,404.80. The trade was a 0.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Tuesday, July 7th, Christine Mikail Cvijic sold 4,200 shares of Neurogene stock. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00.
• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The shares were sold at an average price of $34.82, for a total transaction of $141,404.02.
• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The shares were sold at an average price of $34.06, for a total transaction of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total transaction of $300,000.00.

Neurogene Stock Up 13.0%

Shares of NGNE stock traded up $4.24 during mid-day trading on Tuesday, hitting $36.80. 708,181 shares of the stock were exchanged, compared to its average volume of 246,656. The firm has a fifty day moving average of $29.70 and a 200 day moving average of $23.57. Neurogene Inc. has a 52-week low of $15.93 and a 52-week high of $37.27. The company has a market cap of $581.44 million, a PE ratio of -8.09 and a beta of 1.68.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.09). Equities analysts predict that Neurogene Inc. will post -5.63 EPS for the current year.

Institutional Investors Weigh In On Neurogene

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its position in Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares during the last quarter. Daiwa Securities Group Inc. purchased a new stake in shares of Neurogene in the 4th quarter valued at approximately $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Neurogene during the 4th quarter valued at approximately $165,000. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Neurogene during the 3rd quarter valued at approximately $187,000. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on NGNE. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a report on Tuesday, June 9th. Canaccord Genuity Group cut their price objective on Neurogene to $180.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Rodman & Renshaw started coverage on Neurogene in a report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 target price for the company. Finally, UBS Group set a $70.00 target price on Neurogene in a research report on Wednesday, June 3rd. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $84.83.

Neurogene Company Profile

Neurogene, Inc is a clinical?stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno?associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9?based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.